26.02.2013 - Pharma IP investor Royalty Pharma has made a US$6,5bn take-over bid for Elan Corp. plc after the Irish company sold its bestseller Tysabri to Biogen Idec.
The bid came directly after Elan had sold its multiple sclerosis drug Tysabri (natalizummab) to its long-term partner Biogen Idec, securing the company US$3.25bn. On February 22nd, Elan said it planned a share buyback of US$1bn and will focus on acquisitions after having sold its bestseller. Additionally, the company announced it will refinance its US$600m in debt.
On February 25th, Royalty published a take-over offer of US$11 per share, valuing Elan at US$6.55bn, a 3.8% premium to Elan’s closing share price on February 22nd. Royalty said that it already attempted to start negotiations with Elan on February 18th, after offering the price to Elan’s management. Yesterday, the investor directly asked shareholders if they want to stay invested in a company that has nothing but cash and royalty streams from Tysabri.
Analysts however suggested that Elan would be worth more than US$15 per share. Elan’s Board confirmed the bid, but called the timing of the bid „highly conditional“ and a „proposal , which may or may not lead to an offer being made for the entire share capital of the company“. Pointing to the Tysabri deal, the management added that the company has been working „for more than a year on a number of strategic transactions that would be to the benefit of our public shareholders“. However, any credible proposal will be considered, said the management. After having spun off its antibody drug discovery arm Prothena Corp. plc, Elan is working with giants Johnson & Johnson and Pfizer Inc. on ELND005, a Phase II drug to treat Alzheimer’s disease.
04.05.2016 Barcelona-based epigenetics expert Oryzon Genomics has closed a debt funding round of €10.5m, bringing the total money raised since last year to €27m. The funds will serve to advance the company’s two LSD1 inhibitors in cancer and neurodegeneration.
03.05.2016 Ipsen is strengthening its ties to long-time development partner Oncodesign, a Dijon-based cancer treatment biotech. The French pharma is handing over the pre-clinical pharmacology for its oncology research programmes to Oncodesign.
29.04.2016 Swiss bank Group UBS has raised US$471m (€412m) for the UBS Oncology Impact Fund, which was set up to invest in early-stage cancer treatments. The money raised by the fund, nearly half of which comes from investors in Asia, is the largest amount ever raised for such a cancer investment fund.
27.04.2016 More revenue, more jobs, more financing, more R&D expenditure – all signs point towards sustainable growth in the German biotech sector. These are the results of the most recent company survey 2016, published by biotechnologie.de. The report was once again conducted alongside the biotech standards defined by the organisation for economic cooperation and development (OECD).
21.04.2016 An expert panel’s final report on the fatal drug trial earlier this year in France states that the death of one of the participants was most likely caused by the drug’s toxicity and not by any violation of the rules.
21.04.2016 For up to US$685m (€606m), Dutch ArgenX has outlicensed its human antibody programme ARGX-115 to AbbVie. The pre-clinical immuno-oncology candidate targets a protein believed to contribute to immunosuppressive effects of T-cells.
19.04.2016 British drug developer Heptares Therapeutics and mAb maker Kymab Ltd have partnered up in yet another immuno-oncology collaboration. The companies plan to discover antibody meds targeting a superfamily of receptors.
15.04.2016 Not every company is put off by the current stock market climate. Swiss biopharma company GeNeuro has gone public at Euronext Paris, raising €33m in the process. Others, meanwhile, have to find different ways to raise money.
13.04.2016 Despite political disturbances, 2015 was a good year for the biotech scene in Switzerland. Net sales increased by 5.1% to CHF5,133m and 400 additional people found jobs in the sector. As usual, the new numbers were presented at the annual Swiss Biotech Day – which set new records as well.